Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.

Abstract

The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 patients with DSM-IV schizophrenia. The trial failed to demonstrate any significant difference between the placebo and reboxetine groups on any of the outcome measures. This trial does not suggest that increased noradreneregic drive mediated by reuptake inhibition in patients taking dopamine antagonists is of therapeutic value in schizophrenia.

• Authors: G Schutz, M Berk
• Journal: International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 16 Issue 5 Pg. 275-8 (Sep 2001) ISSN: 0268-1315 [Print] England
• PMID: 11552770 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antidepressive Agents
• Morpholines
• Reboxetine
• Haloperidol

Topics

• Adult
• Antidepressive Agents (administration & dosage, adverse effects)
• Chronic Disease
• Depression (diagnosis, drug therapy, psychology)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Haloperidol (administration & dosage, adverse effects)
• Humans
• Male
• Morpholines (administration & dosage, adverse effects)
• Psychiatric Status Rating Scales
• Reboxetine
• Schizophrenia (diagnosis, drug therapy)
• Schizophrenic Psychology
• Treatment Outcome